Use of anesthetics associated to vasoconstrictors for dentistry in patients with cardiopathies. Review of the literature published in the last decade.

Objective: The use of local anesthetics associated to vasoconstrictor agents in dentistry is thoroughly justified and is widely extended, but we cannot ignore the fact that anesthetic infiltration poses risk of complications throughout the dental treatment period. The objective of the present review is to document the reported effects the use of the local anesthetics most widely employed in dentistry, with or without association to vasoconstrictor agents may have in patients with any sort of cardiopathy. Study Design: We have searched for randomized clinical trials on the assessment of the cardiovascular effects of local anesthetics used in dentistry, without limits as regards age or sex, conducted in patients with any type of cardiopathy which were published during the last decade and were index-linked in Cochrane, Embase and Medline. Results: We have found six randomized clinical trials index-linked in Medline and Cochrane in the past ten years. These trials compare different types of anesthetics: lidocaine 2%, mepivacaine 2%, prilocaine 2% , associated or not to different vasoconstrictor concentrations such as adrenaline or felypressin. The cardiopathies affecting the patients included in the different trials range from hypertension, ischemic heart disease, arrythmias, chronic coronary disease to heart transplantation. Conclusions: The use of anesthetics associated to vasoconstrictor agents is justified in the case of patients with cardiopathies (once we get over the period in which any type of dental manipulation is contraindicated) and in controlled hypertensive patients. In any case, we must be very careful with the choice and execution of the anesthetic technique, being it possible to use a dose between 1.8 and 3.6 ml, on a general basis. Further studies are necessary to establish the effects of these drugs on severe hypertensive patients or in patients with other more advanced cardiopathies.

[1]  H. Giannakopoulos,et al.  Beta-adrenergic blocking agents and dental vasoconstrictors. , 2010, Dental clinics of North America.

[2]  A. Arslan,et al.  Comparison of hemodynamic effects of lidocaine, prilocaine and mepivacaine solutions without vasoconstrictor in hypertensive patients , 2010, Journal of applied oral science : revista FOB.

[3]  A. Reader,et al.  A prospective, randomized, double-blind comparison of 2% lidocaine with 1:100,000 and 1:50,000 epinephrine and 3% mepivacaine for maxillary infiltrations. , 2009, Journal of endodontics.

[4]  C. Grupi,et al.  Effects of epinephrine in local dental anesthesia in patients with coronary artery disease. , 2007, Arquivos brasileiros de cardiologia.

[5]  A. Sousa,et al.  Efeitos cardiovasculares da anestesia local com vasoconstritor durante exodontia em coronariopatas , 2007 .

[6]  J. Yagiela,et al.  Management of the hypertensive dental patient. , 2007, Journal of the California Dental Association.

[7]  M. Tennant,et al.  A concise review of the basic biology and pharmacology of local analgesia. , 2005, Australian dental journal.

[8]  J. M. Thomason,et al.  Effects of dental local anaesthetics in cardiac transplant recipients , 2002, British Dental Journal.

[9]  W. Dick,et al.  Exogenous and Endogenous Plasma Levels of Epinephrine During Dental Treatment Under Local Anesthesia , 1992, Regional Anesthesia & Pain Medicine.

[10]  J. Whitwam,et al.  The current status of pulse oximetry , 1986, Anaesthesia.